NAD+-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease

Raffaele Cerutti, Eija Pirinen, Costanza Lamperti, Silvia Marchet, Anthony A. Sauve, Wei Li, Valerio Leoni, Eric A. Schon, Françoise Dantzer, Johan Auwerx, Carlo Viscomi, Massimo Zeviani

Research output: Contribution to journalArticlepeer-review

Abstract

Mitochondrial disorders are highly heterogeneous conditions characterized by defects of the mitochondrial respiratory chain. Pharmacological activation of mitochondrial biogenesis has been proposed as an effective means to correct the biochemical defects and ameliorate the clinical phenotype in these severely disabling, often fatal, disorders. Pathways related to mitochondrial biogenesis are targets of Sirtuin1, a NAD+-dependent protein deacetylase. As NAD+ boosts the activity of Sirtuin1 and other sirtuins, intracellular levels of NAD+ play a key role in the homeostatic control of mitochondrial function by the metabolic status of the cell. We show here that supplementation with nicotinamide riboside, a natural NAD+ precursor, or reduction of NAD+ consumption by inhibiting the poly(ADP-ribose) polymerases, leads to marked improvement of the respiratory chain defect and exercise intolerance of the Sco2 knockout/knockin mouse, a mitochondrial disease model characterized by impaired cytochrome c oxidase biogenesis. This strategy is potentially translatable into therapy of mitochondrial disorders in humans.

Original languageEnglish
Pages (from-to)1042-1049
Number of pages8
JournalCell Metabolism
Volume19
Issue number6
DOIs
Publication statusPublished - Jun 3 2014

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Physiology

Fingerprint Dive into the research topics of 'NAD<sup>+</sup>-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease'. Together they form a unique fingerprint.

Cite this